HBeAg-negative chronic hepatitis B: Why do I treat my patients with nucleos(t)ide analogues?

Liver International

Volumn 34, Issue SUPPL1, 2014, Pages 120-126

  Viganò, Mauro ^a   Mangia, Giampaolo ^a   Lampertico, Pietro ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Entecavir; HBeAg negative chronic hepatitis B; Nucleos(t)ide analogues; Tenofovir

Indexed keywords

ENTECAVIR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIGEN; NUCLEOSIDE ANALOG; PEGINTERFERON; TENOFOVIR; TENOFOVIR DISOPROXIL;

DRUG SAFETY; DRUG TOLERABILITY; HEPATITIS B; HISTOPATHOLOGY; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; REMISSION; REVIEW; SEROLOGY; VIRUS REPLICATION;

ENTECAVIR; HBEAG-NEGATIVE CHRONIC HEPATITIS B; NUCLEOS(T)IDE ANALOGUES; TENOFOVIR;

ADENINE; AGE FACTORS; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; INDIVIDUALIZED MEDICINE; INTERFERON-ALPHA; NUCLEOSIDES; ORGANOPHOSPHONATES; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; SEX FACTORS; TREATMENT OUTCOME;

EID: 84890867230     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12401     Document Type: Review

References (46)

1. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet 2009; 373: 582-92.
2. Hadziyannis SJ, Papatheodoridis GV. Hepatitis B e antigen negative chronic hepatitis B - natural history and treatment. Semin Liver Dis 2006; 26: 130-41.
3. Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-83.
4. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-2.
5. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2012; 57: 167-85.
6. Viganò M, Lampertico P. Antiviral drugs for HBV liver disease. Expert Opin Biol Ther 2011; 11: 285-300.
7. Zoutendijk R, Reijnders JG, Brown A, et al. Entecavir treatment for chronic hepatitis B: adaptation is not needed for the majority of naïve patients with a partial virological response. Hepatology 2011; 54: 443-51.
8. Baqai SF, Hana Yi D, Gish RG, et al. Profound virologic response in chronic hepatitis B (CHB) patients treated with entecavir. Hepatology 2009; 50: 4 [abstract 476].
9. Yuen MF, Seto WK, Fung J, et al. Three years of continuous entecavir therapy in treatment-naïve chronic hepatitis B patients: VIRAL suppression, viral resistance, and clinical safety. Am J Gastroenterol 2011; 106: 1264-71.
10. Ono A, Suzuki F, Kawamura Y, et al. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients. J Hepatol 2012; 57: 508-14.
11. Lampertico P, Soffredini R, Viganò M, et al. 5-year entecavir treatment in NUC-naive, field-practice patients with chronic hepatitis B showed excellent viral suppression and safety profile but no prevention of HCC in cirrhosis. J Hepatol 2013; 58: S306.
12. Shim JH, Lee HC, Kim KM, et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176-82.
13. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, et al. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. Hepatology 2011; 54: 91-100.
14. Petersen J, Heyne R, Mauss S, et al. Effectiveness of tenofovir for chronic hepatitis B in field practice - 2 year interim results from the prospective German multicenter non-interventional study (GEMINIS). J Hepatol 2013; 58: S313.
15. Hézode C, Causse X, Larrey D, et al. Virological response and tolerance of tenofovir DF (TDF) in the elderly is similar to younger patients in real life practice. J Hepatol 2013; 58: S303.
16. Lampertico P, Soffredini R, Yurdaydin C, et al. Four years of tenofovir monotherapy for NUC naïve field practice European patients suppress HBV replication in most patients with a favourable renal safety profile but do not prevent HCC in patients with or without cirrhosis. Hepatology 2013; 58(Suppl. 1): A933.
17. Marcellin P, Buti M, Gane E, et al. Six years of treatment with Tenofovir DF for chronic hepatitis B virus infection is safe and well tolerated and associated with sustained virological, biochemical and serological responses with no detectable resistance. Hepatology 2012; 56: 4 [abstract 374].
18. Liaw YF, Sheen IS, Lee CM, et al. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72.
19. Lampertico P, Viganò M, Colombo M. Partial response to entecavir and tenofovir in naive patients with chronic epatiti B: clinical relevance and management. Curr Hepatitis Rep 2012; 11: 90-4.
20. Viganò M, Mangia G, Lampertico P. Results of treatment of chronic hepatitis B with pegylated interferon. Clin Liver Dis 2013; 17: 425-43.
21. Fontana RJ. Side effects of long-term oral antiviral therapy for hepatitis B. Hepatology 2009; 49: S185-95.
22. Manns MP, Akarca US, Chang TT, et al. Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901. Expert Opin Drug Saf 2012; 11: 361-8.
23. Lange CM, Bojunga J, Hofmann WP, et al. Severe lactic acidosis during treatment of chronic hepatitis B with entecavir in patients with impaired liver function. Hepatology 2009; 50: 2001-6.
24. Baraclude Package insert 2012. Available at packageinserts.bms.com/pi/pi_baraclude.pdf. Accessed November 2013.
25. Hall AM, Hendry BM, Nitsch D, Connolly JO. Tenofovir-associated kidney toxicity in HIV-infected patients: a review of the evidence. Am J Kidney Dis 2011; 57: 773-80.
26. Fung S, Kwan P, Horban A, et al. Tefnofovir DF (TDF) is safe and well tolerated in chronic hepatitis B (CHB) patients with pre-existing mild renal impairment. J Hepatolo 2013; 58: S301.
27. Viganò M, Lampertico P, Mangia G, et al. Incidence and clinical consequences of reduced tubular phosphate re-absorption in naïve chronic hepatitis B patients either untreated or treated with tenofovir for 2 years in a field practice. Hepatology 2013; 58(Suppl. 1): 978A.
28. Gracey DM, Snelling P, McKenzie P, Strasser SI. Tenofovir-associated Fanconi Syndrome in patients with chronic hepatitis B monoinfection. Antivir Ther 2013; doi: 10.3851/IMP2649. [Epub ahead of print].
29. Viganò M, Brocchieri A, Mangia G, et al. A tenofovir-associated Fanconi syndrome in a chronic hepatitis B patient previously exposed to adefovir dipivoxil. J Hepatol 2013; Submitted.
30. Lampertico P, Mangia G, Viganò M, et al. Tenofovir monotherapy is effective for Adefovir experienced patients but requires careful monitoring of glomerular and tubular function and proactive dose reductions: a 4-year study in 320 patients. Hepatology 2013; 58(Suppl. 1): 649A.
31. Marcellin P, Asselah T. Long-term therapy for chronic hepatitis B: hepatitis B virus DNA suppression leading to cirrhosis reversal. J Gastroenterol Hepatol 2013; 28: 912-23.
32. Chang TT, Liaw Y-F, Wu SS, et al. Long-term entecavir therapy results in reversal fibrosis/cirrhosis and continued histologic improvement in chronic hepatitis B patients. Hepatology 2010; 52: 886-937.
33. Schiff ER, Lee SS, Chao YC, et al. Long-term treatment with entecavir induces reversal of advanced fibrosis or cirrhosis in patients with chronic hepatitis B. Clin Gastroenterol Hepatol 2011; 9: 274-6.
34. Marcellin P, Gane E, Buti M, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-75.
35. Zoutendijk R, Reijnders JG, Zoulim F, et al. Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013; 62: 760-5.
36. Wong GL, Chan HL, Mak CH, et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; doi: 10.1002/hep.26301. [Epub ahead of print].
37. Kim WR, Berg T, Loomba R, et al. Long term tenofovir disoproxil fumarate (TDF) therapy and the risk of hepatocellular carcinoma. J Hepatol 2013; 58: S19.
38. Martinot-Peignoux M, Lapalus M, Asselah T, Marcellin P. The role of HBsAg quantification for monitoring natural history and treatment outcome. Liver Int 2013; 33(Suppl. 1): 125-32.
39. Reijnders JG, Rijckborst V, Sonneveld MJ, et al. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol 2011; 54: 449-54.
40. Marcellin P, Heathcote EJ, Buti M, et al. HBsAg kinetics in patients with chronic hepatitis B (CHB) treated with tenofovir disoproxil fumarate (TDF) for up to 4 years. J Hepatol 2011; 54: 740A.
41. Zoutendijk R, Zaaijer HL, de Vries-Sluijs TE, et al. Hepatitis B surface antigen declines and clearance during long-term tenofovir therapy in patients coinfected with HBV and HIV. J Infect Dis 2012; 206: 974-80.
42. Jeng WJ, Sheen IS, Chen YC, et al. Off therapy durability of response to Entecavir therapy in hepatitis B e antigen negative chronic hepatitis B patients. Hepatology 2013; doi: 10.1002/hep.26549. [Epub ahead of print]
43. Kittner JM, Sprinzl MF, Grambihler A, et al. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J Clin Virol 2012; 54: 93-5.
44. Ouzan D, Penaranda G, Joly H, et al. Add-on of Peg interferon to a stable nucleoside regimen led to loos of HBsAg in chronic hepatitis HBeAg-negative patients. Hepatology 2011; 54: 1015A.
45. Lampertico P, Invernizzi F, Soffredini R, et al. Add-on Peg-IFN improves HBsAg kinetics in patients long-term fully suppressed by nucleos(t)ide analogs. J Hepatol 2012; 56: S2-207.
46. Wu Z, Sheng J, Li L, et al. Improvement of HBsAg loss by additional PegIFN in nucleoside analogs treated chronic hepatitis B patients. Hepatology 2012; 56: 404A.